logging in or signing up The new obesity guidance Flemel Download Post to : URL : Related Presentations : Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Uploaded from authorPOINT Insert YouTube videos in PowerPont slides with aS Desktop Copy embed code: (To copy code, click on the text box) Embed: URL: Thumbnail: WordPress Embed Customize Embed The presentation is successfully added In Your Favorites. Views: 863 Category: News & Reports.. License: All Rights Reserved Like it (0) Dislike it (0) Added: August 11, 2007 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript The new obesity guidance: The new obesity guidance Steve Garbutt Introduction: Introduction NICE due to report on Obesity on 27 February 2007 Brought forward to report on 6 November 2006 Consultation on first (and only) draft from 16 March 2006 Aims and objectives: Aims and objectives To recap on the existing guidance and then compare the new guidance in the draft report for each of the following interventions Orlistat (Xenical) Sibutramine (Reductil) Bariatric surgery Orlistat – existing guidance: Orlistat – existing guidance Technology appraisal 22 NICE March 2001 Orlistat - existing: Orlistat - existing Age 18-75 and BMIandgt;30 or 28 plus co-morbidity Lose 2.5kg in one month by diet and exercise before initiate treatment Lose 5% at 3 months Lose 10% at six months Not usually recommended beyond 12 months and never beyond 24 months Orlistat - proposed: Orlistat - proposed Same BMI’s apply No 'run in' period No 10% at six month rule Orlistat - proposed: Orlistat - proposed Recognise that diabetics may have slower rate of weight loss and that 'less strict goals of weight loss…should be agreed with the individual' Orlistat - proposed: Orlistat - proposed Use after 12 months, usually for maintenance, should be after discussion with the individual about risks and benefits Orlistat: Orlistat Use in 12-16 year olds with severe physical or psychological co-morbidity under specialist supervision and with a 6 month trial period Use under 12 in exceptional circumstances by specialists only Sibutramine - existing: Sibutramine - existing Technology appraisal 31 NICE October 2001 Sibutramine - existing: Sibutramine - existing Same BMI’s as orlistat 18-65 year olds who have made 'serious attempts to lose weight by diet, exercise and/or other changes in their behaviour' Sibutramine - existing: Sibutramine - existing Must lose 2kg in first month Must lose 5% at 3 months Sibutramine - proposed: Sibutramine - proposed 'emerging evidence of longer term use for maintenance and prescribers should be aware of the latest evidence' For children within the same limitations as orlistat Obesity surgery: Obesity surgery Technology appraisal 46 NICE July 2002 Obesity surgery - existing: Obesity surgery - existing BMI andgt;40 or andgt;35 and comorbidity Only if been receiving intensive management in a hospital obesity service All appropriate and available non-surgical measure been adequately tried and failed to maintain weight loss Obesity surgery - existing: Obesity surgery - existing Generally fit for anaesthesia and surgery Understand the need for long term follow up No physical or psychological contraindication as assessed by specialist multidisciplinary unit Obesity surgery – existing: Obesity surgery – existing No firm evidence for efficacy or cost effectiveness of one particular procedure and so should be chosen between surgeon and individual according to best available evidence Surgery - proposed: Surgery - proposed Surgery recommended as a first line option in individuals with BMIandgt;50 and in whom surgery is considered appropriate Surgery - proposed: Surgery - proposed Drug treatment no recommended as first line treatment in individuals considered suitable for surgery However may be used as an interim measure to maintain or reduce weight prior to surgery where waiting times are considered excessive Surgery - proposed: Surgery - proposed Procedure chosen according to degree of obesity, co-morbidity, evidence, facilities and experience of surgeon Surgery - proposed: Surgery - proposed Children may be considered in an adult unit where specialist paediatric dietetic, anaesthetic, psychologist and physician care also available Slide22: You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.
The new obesity guidance Flemel Download Post to : URL : Related Presentations : Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Uploaded from authorPOINT Insert YouTube videos in PowerPont slides with aS Desktop Copy embed code: (To copy code, click on the text box) Embed: URL: Thumbnail: WordPress Embed Customize Embed The presentation is successfully added In Your Favorites. Views: 863 Category: News & Reports.. License: All Rights Reserved Like it (0) Dislike it (0) Added: August 11, 2007 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript The new obesity guidance: The new obesity guidance Steve Garbutt Introduction: Introduction NICE due to report on Obesity on 27 February 2007 Brought forward to report on 6 November 2006 Consultation on first (and only) draft from 16 March 2006 Aims and objectives: Aims and objectives To recap on the existing guidance and then compare the new guidance in the draft report for each of the following interventions Orlistat (Xenical) Sibutramine (Reductil) Bariatric surgery Orlistat – existing guidance: Orlistat – existing guidance Technology appraisal 22 NICE March 2001 Orlistat - existing: Orlistat - existing Age 18-75 and BMIandgt;30 or 28 plus co-morbidity Lose 2.5kg in one month by diet and exercise before initiate treatment Lose 5% at 3 months Lose 10% at six months Not usually recommended beyond 12 months and never beyond 24 months Orlistat - proposed: Orlistat - proposed Same BMI’s apply No 'run in' period No 10% at six month rule Orlistat - proposed: Orlistat - proposed Recognise that diabetics may have slower rate of weight loss and that 'less strict goals of weight loss…should be agreed with the individual' Orlistat - proposed: Orlistat - proposed Use after 12 months, usually for maintenance, should be after discussion with the individual about risks and benefits Orlistat: Orlistat Use in 12-16 year olds with severe physical or psychological co-morbidity under specialist supervision and with a 6 month trial period Use under 12 in exceptional circumstances by specialists only Sibutramine - existing: Sibutramine - existing Technology appraisal 31 NICE October 2001 Sibutramine - existing: Sibutramine - existing Same BMI’s as orlistat 18-65 year olds who have made 'serious attempts to lose weight by diet, exercise and/or other changes in their behaviour' Sibutramine - existing: Sibutramine - existing Must lose 2kg in first month Must lose 5% at 3 months Sibutramine - proposed: Sibutramine - proposed 'emerging evidence of longer term use for maintenance and prescribers should be aware of the latest evidence' For children within the same limitations as orlistat Obesity surgery: Obesity surgery Technology appraisal 46 NICE July 2002 Obesity surgery - existing: Obesity surgery - existing BMI andgt;40 or andgt;35 and comorbidity Only if been receiving intensive management in a hospital obesity service All appropriate and available non-surgical measure been adequately tried and failed to maintain weight loss Obesity surgery - existing: Obesity surgery - existing Generally fit for anaesthesia and surgery Understand the need for long term follow up No physical or psychological contraindication as assessed by specialist multidisciplinary unit Obesity surgery – existing: Obesity surgery – existing No firm evidence for efficacy or cost effectiveness of one particular procedure and so should be chosen between surgeon and individual according to best available evidence Surgery - proposed: Surgery - proposed Surgery recommended as a first line option in individuals with BMIandgt;50 and in whom surgery is considered appropriate Surgery - proposed: Surgery - proposed Drug treatment no recommended as first line treatment in individuals considered suitable for surgery However may be used as an interim measure to maintain or reduce weight prior to surgery where waiting times are considered excessive Surgery - proposed: Surgery - proposed Procedure chosen according to degree of obesity, co-morbidity, evidence, facilities and experience of surgeon Surgery - proposed: Surgery - proposed Children may be considered in an adult unit where specialist paediatric dietetic, anaesthetic, psychologist and physician care also available Slide22: